Abstract
Purpose: CMS has identified readmission of patients within 30 days of discharge as a targeted quality metric and has instituted financial penalties to encourage hospitals to reduce readmissions. The aims of this study were to examine the rate of 30-day admissions after transarterial chemoembolization (TACE) at a single institution and to identify potential factors associated with readmission. Methods: A total of 275 patients were identified who underwent a total of 457 TACE procedures over a 21-year period. Their electronic medical records were reviewed to evaluate the 30-day readmission rate in all patients undergoing TACE, and multiple logistic regression analysis was used to ascertain any clinical or demographic factors affecting the risk for readmission. Results: Nineteen patients (4.2%) required readmission to the hospital within 30 days; 11 of these readmissions were directly attributable to TACE, with inpatient stays upon readmission ranging from 2 to 27 days. Fourteen patients (3.1%) returned to the emergency department (ED) within 30 days of TACE. Medicare patients were more likely to be readmitted to the hospital or require emergency department treatment within 30 days than patients with private health insurance (P = .006). Patients with worse performance status (Eastern Cooperative Oncology Group) were also more likely to require emergency department care within 30 days (P = .04). Conclusions: TACE patients are at risk for readmission, often related to underlying medical comorbidities. Although extensively studied in other specialties, the Hospital Readmissions Reduction Program has received little attention in the radiology literature, and radiologists should familiarize themselves with this continually expanding initiative.
| Original language | English (US) |
|---|---|
| Journal | Journal of the American College of Radiology |
| DOIs | |
| State | Accepted/In press - 2016 |
Fingerprint
Keywords
- Chemoembolization
- Oncology
- Readmissions
- TACE
- Transarterial
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Transarterial Chemoembolization in the Coming Era of Decreased Reimbursement for Readmissions. / McCarthy, Colin J.; Zhu, Andrew X.; Alansari, Shehab A.; Oklu, Rahmi.
In: Journal of the American College of Radiology, 2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Transarterial Chemoembolization in the Coming Era of Decreased Reimbursement for Readmissions
AU - McCarthy, Colin J.
AU - Zhu, Andrew X.
AU - Alansari, Shehab A.
AU - Oklu, Rahmi
PY - 2016
Y1 - 2016
N2 - Purpose: CMS has identified readmission of patients within 30 days of discharge as a targeted quality metric and has instituted financial penalties to encourage hospitals to reduce readmissions. The aims of this study were to examine the rate of 30-day admissions after transarterial chemoembolization (TACE) at a single institution and to identify potential factors associated with readmission. Methods: A total of 275 patients were identified who underwent a total of 457 TACE procedures over a 21-year period. Their electronic medical records were reviewed to evaluate the 30-day readmission rate in all patients undergoing TACE, and multiple logistic regression analysis was used to ascertain any clinical or demographic factors affecting the risk for readmission. Results: Nineteen patients (4.2%) required readmission to the hospital within 30 days; 11 of these readmissions were directly attributable to TACE, with inpatient stays upon readmission ranging from 2 to 27 days. Fourteen patients (3.1%) returned to the emergency department (ED) within 30 days of TACE. Medicare patients were more likely to be readmitted to the hospital or require emergency department treatment within 30 days than patients with private health insurance (P = .006). Patients with worse performance status (Eastern Cooperative Oncology Group) were also more likely to require emergency department care within 30 days (P = .04). Conclusions: TACE patients are at risk for readmission, often related to underlying medical comorbidities. Although extensively studied in other specialties, the Hospital Readmissions Reduction Program has received little attention in the radiology literature, and radiologists should familiarize themselves with this continually expanding initiative.
AB - Purpose: CMS has identified readmission of patients within 30 days of discharge as a targeted quality metric and has instituted financial penalties to encourage hospitals to reduce readmissions. The aims of this study were to examine the rate of 30-day admissions after transarterial chemoembolization (TACE) at a single institution and to identify potential factors associated with readmission. Methods: A total of 275 patients were identified who underwent a total of 457 TACE procedures over a 21-year period. Their electronic medical records were reviewed to evaluate the 30-day readmission rate in all patients undergoing TACE, and multiple logistic regression analysis was used to ascertain any clinical or demographic factors affecting the risk for readmission. Results: Nineteen patients (4.2%) required readmission to the hospital within 30 days; 11 of these readmissions were directly attributable to TACE, with inpatient stays upon readmission ranging from 2 to 27 days. Fourteen patients (3.1%) returned to the emergency department (ED) within 30 days of TACE. Medicare patients were more likely to be readmitted to the hospital or require emergency department treatment within 30 days than patients with private health insurance (P = .006). Patients with worse performance status (Eastern Cooperative Oncology Group) were also more likely to require emergency department care within 30 days (P = .04). Conclusions: TACE patients are at risk for readmission, often related to underlying medical comorbidities. Although extensively studied in other specialties, the Hospital Readmissions Reduction Program has received little attention in the radiology literature, and radiologists should familiarize themselves with this continually expanding initiative.
KW - Chemoembolization
KW - Oncology
KW - Readmissions
KW - TACE
KW - Transarterial
UR - http://www.scopus.com/inward/record.url?scp=84977532140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84977532140&partnerID=8YFLogxK
U2 - 10.1016/j.jacr.2016.04.030
DO - 10.1016/j.jacr.2016.04.030
M3 - Article
JO - JACR Journal of the American College of Radiology
JF - JACR Journal of the American College of Radiology
SN - 1558-349X
ER -